We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

New Serology Assay Accelerates COVID-19 Research through Rapid Characterization of Immune Response to SARS-CoV-2 Antigens

By LabMedica International staff writers
Posted on 20 Oct 2020
Print article
A new SARS-CoV-2 multi-antigen assay for Simple Western offers quantitative characterization of patient serum or plasma derived human IgG antibodies reactive against recombinant Nucleocapsid protein (N), S1 receptor binding domain protein (RBD), S1 subunit full length, S2 subunit full length, and Spike (S1+S2) viral antigens within one 3-hour run.

Bio-Techne Corporation (Minneapolis, Minn., USA) has launched its SARS-CoV-2 Multi-Antigen Serology Module for Jess and Wes Simple Western automated western blotting systems. ProteinSimple's Simple Western systems are automated, hands-free western blotting platforms that can be used for antigen-down serology assays for SARS-CoV-2. The Simple Western serology assay moves beyond 1- or 2-antigen serology assays to measure serum or plasma antibodies reactive against five SARS-CoV-2 antigens simultaneously, providing information-rich views into antibody binding profiles across patients and over the time course of the infection. The SARS-CoV-2 multi-antigen serology assay runs on Jess and Wes systems, enabling the processing of 23 patient samples in three hours. This approach has promise as a tool to rapidly characterize patient immune response and as an orthogonal confirmatory test to validate results derived from lateral flow, ELISA (enzyme-linked immunosorbent assay) or other immunoassay serology techniques.

"We are excited about the multi-antigen views this serology assay provides COVID-19 researchers and vaccine developers, while promising to speed up time to data," said Bob Gavin, Sr. Vice President of Bio-Techne's, Analytical Solutions Division. "It leverages Simple Western strengths of minimal set-up time, hands-free operation, and fully analyzed results in three hours."

"The new SARS-CoV-2 Multi-Antigen Serology Module is a powerful advancement in the fight against COVID-19," said Dave Eansor, President of Bio-Techne's Protein Sciences Segment. "At Bio-Techne, we are committed to arming COVID-19 vaccine developers and scientists researching the SARS-CoV-2 immune response with cutting edge technology including the new Simple Western serology assay and Kantaro SeroIndex RUO ELISA kit."

Related Links:
Bio-Techne Corporation

Print article


Copyright © 2000-2020 Globetech Media. All rights reserved.